Clinical and Histopathological Predictors of Recurrence in Uterine Smooth Muscle Tumor of Uncertain Malignant Potential (STUMP): A Multicenter Retrospective Cohort Study of Tertiary Centers.
Journal
Annals of surgical oncology
ISSN: 1534-4681
Titre abrégé: Ann Surg Oncol
Pays: United States
ID NLM: 9420840
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
received:
30
12
2021
accepted:
21
07
2022
pubmed:
18
8
2022
medline:
11
11
2022
entrez:
17
8
2022
Statut:
ppublish
Résumé
The term uterine smooth muscle tumor of uncertain malignant potential (STUMP) indicates a rare, equivocal entity between benign leiomyomas and leiomyosarcomas. In the present study, we evaluated a comprehensive range of clinical, surgical, and pathological features in a large multicenter series of patients with STUMP to identify risk factors for recurrence. This is a retrospective study performed by collecting consecutive cases diagnosed between January 2000 and December 2020 in five tertiary centers. Associations between STUMP recurrence and clinicopathological characteristics as well as surgical treatment modality were investigated. Eighty-seven patients affected by STUMP were considered. Of them, 18 cases (20.7%) recurred: 11 as leiomyosarcoma (LMS) and 7 as STUMP. The mean time to recurrence was 79 months. We found that fragmentation/morcellation, epithelioid features, high mitotic count, Ki-67 value > 20%, progesterone receptor (PR) < 83%, and p16 diffuse expression were associated with higher risk of recurrence and shorter recurrence-free survival (RFS). Furthermore, morcellation/fragmentation and mitotic count remained independent risk factors for recurrence and shorter RFS after multivariate analysis, while the presence of epithelioid features was an independent risk factor for recurrence only. Our results suggest that morcellation is associated with risk of recurrence and shorter RFS, thus it should be avoided if a STUMP is suspected preoperatively. Epithelioid features, high proliferation activity, low PR expression, and diffuse p16 expression are also unfavorable prognostic factors, so patients presenting these features should be closely followed up.
Sections du résumé
BACKGROUND
BACKGROUND
The term uterine smooth muscle tumor of uncertain malignant potential (STUMP) indicates a rare, equivocal entity between benign leiomyomas and leiomyosarcomas. In the present study, we evaluated a comprehensive range of clinical, surgical, and pathological features in a large multicenter series of patients with STUMP to identify risk factors for recurrence.
METHODS
METHODS
This is a retrospective study performed by collecting consecutive cases diagnosed between January 2000 and December 2020 in five tertiary centers. Associations between STUMP recurrence and clinicopathological characteristics as well as surgical treatment modality were investigated.
RESULTS
RESULTS
Eighty-seven patients affected by STUMP were considered. Of them, 18 cases (20.7%) recurred: 11 as leiomyosarcoma (LMS) and 7 as STUMP. The mean time to recurrence was 79 months. We found that fragmentation/morcellation, epithelioid features, high mitotic count, Ki-67 value > 20%, progesterone receptor (PR) < 83%, and p16 diffuse expression were associated with higher risk of recurrence and shorter recurrence-free survival (RFS). Furthermore, morcellation/fragmentation and mitotic count remained independent risk factors for recurrence and shorter RFS after multivariate analysis, while the presence of epithelioid features was an independent risk factor for recurrence only.
CONCLUSIONS
CONCLUSIONS
Our results suggest that morcellation is associated with risk of recurrence and shorter RFS, thus it should be avoided if a STUMP is suspected preoperatively. Epithelioid features, high proliferation activity, low PR expression, and diffuse p16 expression are also unfavorable prognostic factors, so patients presenting these features should be closely followed up.
Identifiants
pubmed: 35976464
doi: 10.1245/s10434-022-12353-y
pii: 10.1245/s10434-022-12353-y
pmc: PMC9640445
doi:
Types de publication
Multicenter Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
8302-8314Subventions
Organisme : The present study was supported by grants from Rete Oncologica del Piemonte e Valle d'Aosta and Fondazione Cassa di Risparmio di Torino
ID : file number: 2021.0553).
Commentaires et corrections
Type : CommentIn
Type : ErratumIn
Informations de copyright
© 2022. The Author(s).
Références
Ip PPC, Cheung ANY, Clement PB. Uterine smooth muscle tumors of uncertain malignant potential (STUMP): a clinicopathologic analysis of 16 cases. Am J Surg Pathol. 2009;33(7):992–1005. https://doi.org/10.1097/PAS.0b013e3181a02d1c .
doi: 10.1097/PAS.0b013e3181a02d1c
pubmed: 19417585
Guntupalli SR, Ramirez PT, Anderson ML, Milam MR, Bodurka DC, Malpica A. Uterine smooth muscle tumor of uncertain malignant potential: a retrospective analysis. Gynecol Oncol. 2009;113(3):324–6. https://doi.org/10.1016/j.ygyno.2009.02.020 .
doi: 10.1016/j.ygyno.2009.02.020
pubmed: 19342083
pmcid: 8248445
Ng JSY, Han A, Chew SH, Low J. A clinicopathologic study of uterine smooth muscle tumors of uncertain malignant potential (STUMP). Ann Acad Med Singap. 2010;39(8):625–8.
pubmed: 20838704
Dańska-Bidzińska A, Bakuła-Zalewska E, Nasierowska-Guttmejer A, et al. Smooth muscle tumor of uncertain malignant potential (STUMP)—clinico-pathomorphological analysis of the cases and literature review. Ginekol Pol. 2012;83(6):412–6.
pubmed: 22880459
Dall’Asta A, Gizzo S, Musarò A, et al. Uterine smooth muscle tumors of uncertain malignant potential (STUMP): pathology, follow-up and recurrence. Int J Clin Exp Pathol. 2014;7(11):8136–42.
pubmed: 25550862
pmcid: 4270570
Bacanakgil BH, Deveci M, Karabuk E, Soyman Z. Uterine smooth muscle tumor of uncertain malignant potential: clinicopathologic-sonographic characteristics, follow-up and recurrence. World J Oncol. 2017;8(3):76–80. https://doi.org/10.14740/wjon1031w .
doi: 10.14740/wjon1031w
pubmed: 29147439
pmcid: 5650001
Basaran D, Usubutun A, Salman MC, et al. The clinicopathological study of 21 cases with uterine smooth muscle tumors of uncertain malignant potential: centralized review can purify the diagnosis. Int J Gynecol Cancer. 2018;28(2):233–40. https://doi.org/10.1097/IGC.0000000000001178 .
doi: 10.1097/IGC.0000000000001178
pubmed: 29303932
Gupta M, Laury AL, Nucci MR, Quade BJ. Predictors of adverse outcome in uterine smooth muscle tumours of uncertain malignant potential (STUMP): a clinicopathological analysis of 22 cases with a proposal for the inclusion of additional histological parameters. Histopathology. 2018;73(2):284–98. https://doi.org/10.1111/his.13515 .
doi: 10.1111/his.13515
pubmed: 29537683
Şahin H, Karatas F, Coban G, et al. Uterine smooth muscle tumor of uncertain malignant potential: fertility and clinical outcomes. J Gynecol Oncol. 2019;30(4):e54. https://doi.org/10.3802/jgo.2019.30.e54 .
doi: 10.3802/jgo.2019.30.e54
pubmed: 31074239
pmcid: 6543118
Huo L, Wang D, Wang W, et al. Oncologic and reproductive outcomes of uterine smooth muscle tumor of uncertain malignant potential: a single center retrospective study of 67 cases. Front Oncol. 2020;10:647. https://doi.org/10.3389/fonc.2020.00647 .
doi: 10.3389/fonc.2020.00647
pubmed: 32477938
pmcid: 7240040
Shim JI, Han AKW, Jeon HJ, et al. Clinical experience of uterine smooth muscle tumor of uncertain malignant potential in two gynecological centers: oncological and obstetrical aspects. Eur J Obstet Gynecol Reprod Biol. 2020;246:7–13. https://doi.org/10.1016/j.ejogrb.2020.01.002 .
doi: 10.1016/j.ejogrb.2020.01.002
pubmed: 31927240
Zheng YY, Liu XB, Mao YY, Lin MH. Smooth muscle tumor of uncertain malignant potential (STUMP): a clinicopathologic analysis of 26 cases. Int J Clin Exp Pathol. 2020;13(4):818–26.
pubmed: 32355532
pmcid: 7191150
Bell SW, Kempson RL, Hendrickson MR. Problematic uterine smooth muscle neoplasms: A clinicopathologic study of 213 cases. Am J Surg Pathol. 1994;18(6):535–58.
doi: 10.1097/00000478-199406000-00001
pubmed: 8179071
Smooth muscle tumour of uncertain malignant potential of the uterine corpus. In WHO Classification of Tumours Editorial Board (Eds.), WHO Classification of Tumours, 5th Edition, Female Genital Tumours, p. 279–280. Lyon: International Agency for Research on Cancer, 2020
Cotrino I, Carosso A, Macchi C, et al. Ultrasound and clinical characteristics of uterine smooth muscle tumors of uncertain malignant potential (STUMPs). Eur J Obstet Gynecol Reprod Biol. 2020;251:167–72. https://doi.org/10.1016/j.ejogrb.2020.05.040 .
doi: 10.1016/j.ejogrb.2020.05.040
pubmed: 32505056
Gadducci A, Zannoni GF. Uterine smooth muscle tumors of unknown malignant potential: a challenging question. Gynecol Oncol. 2019;154(3):631–7. https://doi.org/10.1016/j.ygyno.2019.07.002 .
doi: 10.1016/j.ygyno.2019.07.002
pubmed: 31326137
O’Neill CJ, McBride HA, Connolly LE, McCluggage WG. Uterine leiomyosarcomas are characterized by high p16, p53 and MIB1 expression in comparison with usual leiomyomas, leiomyoma variants and smooth muscle tumours of uncertain malignant potential. Histopathology. 2007;50(7):851–8. https://doi.org/10.1111/j.1365-2559.2007.02699.x .
doi: 10.1111/j.1365-2559.2007.02699.x
pubmed: 17543074
Vilos GA, Marks J, Ettler HC, Vilos AG, Prefontaine M, Abu-Rafea B. Uterine smooth muscle tumors of uncertain malignant potential: diagnostic challenges and therapeutic dilemmas: Report of 2 cases and review of the literature. J Minim Invasive Gynecol. 2012;19(3):288–95. https://doi.org/10.1016/j.jmig.2011.12.025 .
doi: 10.1016/j.jmig.2011.12.025
pubmed: 22546421
Mowers EL, Skinner B, McLean K, Reynolds RK. Effects of morcellation of uterine smooth muscle tumor of uncertain malignant potential and endometrial stromal sarcoma: case series and recommendations for clinical practice. J Minim Invasive Gynecol. 2015;22(4):601–6. https://doi.org/10.1016/j.jmig.2015.01.007 .
doi: 10.1016/j.jmig.2015.01.007
pubmed: 25596464
PedraNobre S, Hensley ML, So M, et al. The impact of tumor fragmentation in patients with stage I uterine leiomyosarcoma on patterns of recurrence and oncologic outcome. Gynecol Oncol. 2021;160(1):99–105. https://doi.org/10.1016/j.ygyno.2020.10.020 .
doi: 10.1016/j.ygyno.2020.10.020
Raspagliesi F, Maltese G, Bogani G, et al. Morcellation worsens survival outcomes in patients with undiagnosed uterine leiomyosarcomas: a retrospective MITO group study. Gynecol Oncol. 2017;144(1):90–5. https://doi.org/10.1016/j.ygyno.2016.11.002 .
doi: 10.1016/j.ygyno.2016.11.002
pubmed: 27817933
U.S. Food and Drug Administration. Update: perform only contained morcellation when laparoscopic power morcellation is appropriate. FDA Safety Communication. Silver Spring, MD: FDA; 2020. Available at: https://www.fda.gov/medical-devices/safety-communications/update-perform-only-contained-morcellation-when-laparoscopic-power-morcellation-appropriate-fda .
American College of Obstetricians and Gynecologists’ Committee on Gynecologic Practice. Uterine morcellation for presumed leiomyomas: ACOG Committee Opinion, Number 822. Obstet Gynecol. 2021;137(3):e63–e74. https://doi.org/10.1097/AOG.0000000000004291
Zullo F, Venturella R, Raffone A, Saccone G. In-bag manual versus uncontained power morcellation for laparoscopic myomectomy. Cochrane Database Syst Rev. 2020;5:CD013352. https://doi.org/10.1002/14651858.CD013352.pub2 .
doi: 10.1002/14651858.CD013352.pub2
pubmed: 32374421
Karataşlı V, Çakır İ, Ayaz D, Budak A, Sancı M. Clinicopathologic evaluation of uterine smooth muscle tumors of uncertain malignant potential (STUMP): a single center experience. J Gynecol Obstet Hum Reprod. 2019;48(8):637–42. https://doi.org/10.1016/j.jogoh.2019.03.003 .
doi: 10.1016/j.jogoh.2019.03.003
pubmed: 30898630
Lim D, Alvarez T, Nucci MR, et al. Interobserver variability in the interpretation of tumor cell necrosis in uterine leiomyosarcoma. Am J Surg Pathol. 2013;37(5):650–8. https://doi.org/10.1097/PAS.0b013e3182851162 .
doi: 10.1097/PAS.0b013e3182851162
pubmed: 23552382
Oliva E. Practical issues in uterine pathology from banal to bewildering: the remarkable spectrum of smooth muscle neoplasia. Mod Pathol. 2016;29(Suppl 1):S104-120. https://doi.org/10.1038/modpathol.2015.139 .
doi: 10.1038/modpathol.2015.139
pubmed: 26715170
Atkins K, Bell S, Kempson R, et al. Epithelioid smooth muscle of the uterus. Mod Pathol. 2001;14:132A.
Devereaux KA, Kunder CA, Longacre TA. ALK-rearranged tumors are highly enriched in the STUMP subcategory of uterine tumors. Am J Surg Pathol. 2019;43(1):64–74. https://doi.org/10.1097/PAS.0000000000001083 .
doi: 10.1097/PAS.0000000000001083
pubmed: 29794871
Guillou L, Coindre JM, Bonichon F, et al. Comparative study of the National Cancer Institute and French Federation of Cancer Centers Sarcoma Group grading systems in a population of 410 adult patients with soft tissue sarcoma. J Clin Oncol. 1997;15(1):350–62. https://doi.org/10.1200/JCO.1997.15.1.350 .
doi: 10.1200/JCO.1997.15.1.350
pubmed: 8996162
Dowsett M, Nielsen TO, A’Hern R, et al. Assessment of Ki67 in breast cancer: Recommendations from the International Ki67 in Breast Cancer Working Group. J Natl Cancer Inst. 2011;103(22):1656–64. https://doi.org/10.1093/jnci/djr393 .
doi: 10.1093/jnci/djr393
pubmed: 21960707
pmcid: 3216967
Bustreo S, Osella-Abate S, Cassoni P, et al. Optimal Ki67 cut-off for luminal breast cancer prognostic evaluation: a large case series study with a long-term follow-up. Breast Cancer Res Treat. 2016;157(2):363–71. https://doi.org/10.1007/s10549-016-3817-9 .
doi: 10.1007/s10549-016-3817-9
pubmed: 27155668
pmcid: 4875067
Vissio E, Metovic J, Osella-Abate S, et al. Integration of Ki-67 index into AJCC 2018 staging provides additional prognostic information in breast tumours candidate for genomic profiling. Br J Cancer. 2020;122(3):382–7. https://doi.org/10.1038/s41416-019-0656-6 .
doi: 10.1038/s41416-019-0656-6
pubmed: 31780778
Mayerhofer K, Lozanov P, Bodner K, Bodner-Adler B, Kimberger O, Czerwenka K. Ki-67 expression in patients with uterine leiomyomas, uterine smooth muscle tumors of uncertain malignant potential (STUMP) and uterine leiomyosarcomas (LMS). Acta Obstet Gynecol Scand. 2004;83(11):1085–8. https://doi.org/10.1111/j.0001-6349.2004.00502.x .
doi: 10.1111/j.0001-6349.2004.00502.x
pubmed: 15488127
Travaglino A, Raffone A, Gencarelli A, et al. p53, p16 and ki67 as immunohistochemical prognostic markers in uterine smooth muscle tumors of uncertain malignant potential (STUMP). Pathol Res Pract. 2021;226:153592. https://doi.org/10.1016/j.prp.2021.153592 .
doi: 10.1016/j.prp.2021.153592
pubmed: 34481212
Waks AG, Winer EP. Breast cancer treatment: a review. JAMA. 2019;321(3):288–300. https://doi.org/10.1001/jama.2018.19323 .
doi: 10.1001/jama.2018.19323
pubmed: 30667505
Zhao D, Zhang F, Zhang W, He J, Zhao Y, Sun J. Prognostic role of hormone receptors in ovarian cancer: a systematic review and meta-analysis. Int J Gynecol Cancer. 2013;23(1):25–33. https://doi.org/10.1097/IGC.0b013e3182788466 .
doi: 10.1097/IGC.0b013e3182788466
pubmed: 23221605
Davidson B, Kjæreng ML, Førsund M, Danielsen HE, Kristensen GB, Abeler VM. Progesterone receptor expression is an independent prognosticator in FIGO Stage I uterine leiomyosarcoma. Am J Clin Pathol. 2016;145(4):449–58. https://doi.org/10.1093/ajcp/aqw030 .
doi: 10.1093/ajcp/aqw030
pubmed: 27149024
Chen L, Yang B. Immunohistochemical analysis of p16, p53, and Ki-67 expression in uterine smooth muscle tumors. Int J Gynecol Pathol. 2008;27(3):326–32. https://doi.org/10.1097/PGP.0b013e31815ea7f5 .
doi: 10.1097/PGP.0b013e31815ea7f5
pubmed: 18580309
Croce S, Ribeiro A, Brulard C, et al. Uterine smooth muscle tumor analysis by comparative genomic hybridization: a useful diagnostic tool in challenging lesions. Mod Pathol. 2015;28(7):1001–10. https://doi.org/10.1038/modpathol.2015.3 .
doi: 10.1038/modpathol.2015.3
pubmed: 25932961
Croce S, Ducoulombier A, Ribeiro A, et al. Genome profiling is an efficient tool to avoid the STUMP classification of uterine smooth muscle lesions: a comprehensive array-genomic hybridization analysis of 77 tumors. Mod Pathol. 2018;31(5):816–28. https://doi.org/10.1038/modpathol.2017.185 .
doi: 10.1038/modpathol.2017.185
pubmed: 29327710
Conconi D, Redaelli S, Lissoni AA, et al. Genomic and epigenomic profile of uterine smooth muscle tumors of uncertain malignant potential (STUMPs) revealed similarities and differences with leiomyomas and leiomyosarcomas. Int J Mol Sci. 2021;22(4):1580. https://doi.org/10.3390/ijms22041580 .
doi: 10.3390/ijms22041580
pubmed: 33557274
pmcid: 7914585
Rizzo A, Ricci AD, Saponara M, et al. Recurrent uterine smooth-muscle tumors of uncertain malignant potential (STUMP): state of the art. Anticancer Res. 2020;40(3):1229–38. https://doi.org/10.21873/anticanres .
doi: 10.21873/anticanres
pubmed: 32132019
Roberts ME, Aynardi JT, Chu CS. Uterine leiomyosarcoma: a review of the literature and update on management options. Gynecol Oncol. 2018;151(3):562–72. https://doi.org/10.1016/j.ygyno.2018.09.010 .
doi: 10.1016/j.ygyno.2018.09.010
pubmed: 30244960